Abstract Background Clear cell renal cell carcinoma (ccRCC) is characterized by a branching genomic architecture in which biallelic VHL inactivation is followed by divergence into PBRM1- or BAP1-mutant lineages, with subsequent acquisition of additional alterations contributing to progression and aggressive behavior. H...
Roy Elias, Vivek Nimgaonkar, B. Xie et al.· The Oncologist· 0 citations
Pancreatic ductal adenocarcinoma (PDA) exhibits marked organotropism, with the liver and lung representing the most common sites of metastatic recurrence. While PDA most often metastasizes to the liver, patients with only lung metastasis have a better overall prognosis, highlighting a role for both tumor-intrinsic pr...
E. Lasse-Opsahl, Daksh Thakkar, Julie M. Clark et al.· Cancer Research· 0 citations
Findings suggest VEGFA–NRP1 signaling drives immune evasion in PDAC and identifies a therapeutic axis for reprogramming TAMs, providing a foundation for future combination immunotherapy strategies.
T. Lopez-Vidal, Jacob T. Mitchell, Kylie Belanger et al.· Cancer Research· 0 citations
Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
S. Haldar, Meredith Wetzel, Jia-Yun Lu et al.· Clinical Cancer Research· 0 citations
A GSTT1HighCD133High stem-like subpopulation in metastatic PDA is identified and an FGFR-dependent signaling axis that sustains this state is identified, representing a potential therapeutic vulnerability.
Delgado Herrera Deborah de la Caridad, Alejandro Arroyo Roman, Riyan N. Campbell et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
